Browsing Tag
AMVUTTRA
3 posts
Can Alnylam Pharmaceuticals’ vutrisiran reverse cardiac damage? HELIOS-B Phase 3 ATTR-CM trial says yes
New HELIOS-B data shows vutrisiran improves cardiac structure and kidney outcomes in ATTR-CM. Find out how Alnylam’s RNAi drug is reshaping treatment.
Can vutrisiran set a new first-line standard in ATTR-CM after HELIOS-B trial results?
Alnylam’s HELIOS-B data shows vutrisiran cuts GI events by up to 49% in ATTR-CM, reinforcing its case as a first-line therapy. Read the full analysis.
How do Vutrisiran’s HELIOS-B results compare with historical standards in ATTR-CM treatment?
Alnylam’s vutrisiran reduces cardiovascular mortality and urgent heart failure visits in ATTR-CM, reinforcing AMVUTTRA’s first-line potential. Read key data now.